Preferred Label : rybrevant;
Origin ID : M000750522;
Related record
https://www.has-sante.fr/jcms/p_3604202/fr/rybrevant-amivantamab-cancer-bronchique-non-a-petites-cellules-exon-19-exon-21
2025
France
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3447827/fr/rybrevant-amivantamab-cancer-bronchique
2023
France
evaluation of the transparency committee
rybrevant
amivantamab
amivantamab
bronchial neoplasms
neoplasm, malignant
Cancer
cancer
bronchus, nos
---
https://www.has-sante.fr/jcms/p_3336657/fr/rybrevant-amivantamab
2022
false
false
false
France
evaluation of the transparency committee
amivantamab
amivantamab
rybrevant
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
2022
false
false
false
Netherlands
French
English
amivantamab
amivantamab
amivantamab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
rybrevant
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
aged
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Exon 20 Mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Gain of Function Mutation
genes, erbb-1
Refractory Lung Non-Small Cell Carcinoma
infusions, intravenous
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
